Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Alcyone Study

Shranjeno v:

Bibliografske podrobnosti
Main Authors:	María‐Victoria Mateos, Jesús F. San Miguel, Michèle Cavo, Joan Bladé Creixenti, Kenshi Suzuki, Andrzej Jakubowiak, Stefan Knop, Chantal Doyen, Paulo Lúcio, Zsolt Nagy, Luděk Pour, Sebastian Grosicki, Andre H Crepaldi, Anna Marina Liberati, Philip Campbell, Tatiana Shelekhova, Sung‐Soo Yoon, Genadi Iosava, Tomoaki Fujisaki, Mamta Garg, Huiling Pei, Maria Krevvata, Robin Carson, Fredrik Borgsten, Meletios Α. Dimopoulos
Format:	Artigo
Jezik:	angleščina
Izdano:	2022
Online dostop:	https://doi.org/10.1182/blood-2022-163347
Oznake:	Označite Brez oznak, prvi označite!

Internet